Effects of Angiotensin Converting Enzyme (ACE) Inhibitors Versus Candesartan in Reducing Cardiovascular Events in Primary Treatment of Hypertension

NCT01152567 · clinicaltrials.gov ↗

COMPLETED

Status

50000

Enrollment

INDUSTRY

Sponsor class

Conditions

Hypertension
Cardiovascular Disease

Sponsor

AstraZeneca